Drug Approval | November 07, 2022
Lupin receives tentative approval from USFDA for Drospirenone Tablets
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
